Tag: Eli Lilly
Eli Lilly Raises 2025 Outlook Amid Strong Drug Sales
Second-Quarter Results Exceed Analyst Expectations Eli Lilly reported stronger-than-expected second-quarter earnings on Thursday, driven by surging demand for its weight loss and diabetes treatments. The [more…]
Novo Nordisk Slips on Q2 Miss and Copycat Drug Pressures
Weak Earnings Follow Downward Guidance Revision Novo Nordisk shares traded lower in premarket action Wednesday after the pharmaceutical company missed Wall Street expectations on both [more…]
Novartis Plans $23B Investment in U.S. Manufacturing Expansion
Novartis Announces Major U.S. Investment Plan Swiss drugmaker Novartis (NOVN.S) announced on Thursday its plan to invest $23 billion to build and expand 10 facilities [more…]
Eli Lilly’s Stock Faces Setback After Weight-Loss Drug Sales Miss Estimates
Eli Lilly, the world’s most valuable drugmaker, saw a sharp decline in its stock price after missing quarterly sales expectations for its blockbuster weight-loss drugs, [more…]
New Weight Loss ETF Bets Big on Industry Leaders
The rising popularity of GLP-1 weight loss drugs has captured the attention of investors, leading Roundhill Investments to launch its GLP-1 & Weight Loss ETF [more…]
